ARTT Center of Excellence UT Health San Antonio




NIDA T32 Training Program:
Postdoctoral Training in Drug Abuse Research
Behavior & Neurobiology

Current Trainees


Highslide JS
Sabrina Blackledge, Ph.D.
Dept. of Psychiatry
Dougherty Lab
blackledge@uthscsa.edu

Coming Soon!

Highslide JS
Brenda Gannon, Ph.D.
Dept. of Pharmacology
Collins Lab
gannonb@uthscsa.edu

As a member of the Collins laboratory, my research is aimed at understanding factors that mediate drug-taking and drug-seeking behaviors.
My current research uses behavioral and pharmacological assays such as intravenous self-administration, drug discrimination, and locomotor activity to investigate vulnerability to stimulant abuse and to evaluate potential treatments for drug abuse. This includes quantitative assessments of the abuse-related and toxic effects of common “bath salt” constituents (e.g., alpha-PVP, MDPV, and methylone) and comparisons to other well-known stimulant drugs of abuse (e.g., methamphetamine and cocaine).

Highslide JS
T. Lee Gilman, Ph.D.
Dept. of Cellular and Integrative Physiology
Daws Lab
gilmant@uthscsa.edu

In the Daws Lab, I am using a mouse model to investigate how constitutive loss of serotonin transporter, a high-affinity/low-capacity transporter, promotes upregulation of the low-affinity/high-capacity transporter organic cation transporter 3 (OCT3) and how this may moderate ethanol consumption. Additional experiments involve investigating how lifelong loss of OCT3 or the plasma membrane monoamine transporter might alter astrocyte morphology in the mouse brain, and how dopamine transporter function is dysregulated in eating disorders using a rat activity-based anorexia model.

Highslide JS
Audrey Hager, Ph.D.
Dept. of Cellular and Integrative Physiology
Daws Lab
hagera@uthscsa.edu

As a postdoctoral fellow in Dr. Daws' Lab I research neuroplasticity in the midbrain and the role of dopamine neurons in addiction and Parkinson's disease.

Highslide JS
Peter Weed, Ph.D.
Dept. of Pharmacology
France Lab
weedp@uthscsa.edu

Opioid analgesics are currently the primary treatment for chronic pain. However, therapeutic doses have several untoward side effects, including tolerance to the analgesic effects and physical dependence. Our laboratory has identified that co-administration of a cannabinoid agonist with an opioid can increase the analgesic effect, thus reducing the required dose. My projects in the France laboratory are exploring the therapeutic potential of these opioid-cannabinoid combinations. A primary goal of the research is to characterize the development of tolerance and dependence during chronic administration of opioid-cannabinoid combinations in an assay of analgesia.

The project described is supported by Award Number T32DA031115 from the National Institute On Drug Abuse. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute On Drug Abuse or the National Institutes of Health.